Tiziana Life Sciences has applied to the US FDA for orphan drug designation for its intranasal foralumab to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disorder with no approved disease-modifying treatments. MSA severely impacts autonomic and motor functions, leading to disability and shortened life expectancy. The designation, if granted, would offer seven years of market exclusivity and other regulatory benefits. Foralumab is currently in a Phase 2a trial assessing its effects on brain inflammation and clinical outcomes, aiming to provide a novel immune-based therapy for this devastating disease.
Tiziana Life Sciences' FDA orphan drug status application for nasal MSA therapy is the subject, with this Pluang Health sector market data for context. Of 100 priced Health-sector US stocks tradable on Pluang, 45 rose and 50 fell today. Notable movers include AMWL at USD 13.54 with a 3.04% increase and 100% sell order activity, DGX at USD 238.50 up 2.82% with 100% buy order activity, and CTXR at USD 0.54 down 2.60% with 97% buy order activity. Data is as of Sep 30, 2026 19:11 WIB.
Conagra Brands reported a 1.4% decline in first-quarter revenue to $2.6 billion, with organic net sales down 1.1%, causing shares to fall 4.6%. Despite the sales drop, adjusted earnings per share rose 5.1% to $0.41, beating analyst estimates of $0.28...
Deutsche Bank has increased its target price for Vodafone Group PLC to 160p from 150p and maintained a 'buy' rating, citing fewer risks and a stronger earnings and cash flow outlook. The bank noted improved investor sentiment following Xavier Niel’s ...
Cisco's stock recently pulled back, presenting a buying opportunity before the October 2 record date for its next 42-cent quarterly dividend. The company benefits from accelerating growth driven by AI data center demand, with fiscal 2026 revenue up n...
Meta's stock has surged 25% in the past month as the company invests heavily—over $130 billion—in AI technology, aiming to transform its advertising business. Despite strong revenue growth and increased AI-driven ad engagement, Meta faces margin pres...
Cinemark and CJ 4DPLEX announced a deal to add 20 new SCREENX auditoriums—17 in the U.S. and 3 in Latin America—by 2026. This expansion increases Cinemark's U.S. SCREENX locations to 30, enhancing premium immersive movie experiences ahead of major re...
